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Abstract: Background: Atrial fibrillation (AF) shares several risk factors with atherosclerosis.
We investigated the association between total carotid plaque number (TPN) and long-term prognosis
in ischemic stroke patients with AF. Methods: A total of 392 ischemic stroke patients with
AF who underwent carotid ultrasonography were enrolled. TPN was assessed using B-mode
ultrasound. The patients were categorized into two groups according to best cutoff values for TPN
(TPN ≤ 4 vs. TPN ≥ 5). The long-term risk of major adverse cardiovascular events (MACE) and
mortality according to TPN was investigated using a Cox hazard model. Results: After a mean
follow-up of 2.42 years, 113 patients (28.8%) had developed MACE and 88 patients (22.4%) had
died. MACE occurred more frequently in the TPN ≥ 5 group than in the TPN ≤ 4 group (adjusted
hazard ratio [HR], 1.50; 95% confidence interval [CI], 1.01–2.21; p < 0.05). Moreover, the TPN ≥ 5
group showed an increased risk of all-cause mortality (adjusted HR, 2.69; 95% CI, 1.40–5.17; p < 0.05).
TPN along with maximal plaque thickness and intima media thickness showed improved prognostic
utility when added to the variables of the CHAD2DS2-VASc score. Conclusion: TPN can predict the
long-term outcome of ischemic stroke patients with AF. Adding TPN to the CHAD2DS2-VASc score
increases the predictability of outcome after stroke.
Keywords: atrial fibrillation; cerebral infarction; carotid stenosis; ultrasonography; outcomes
1. Introduction
Atrial fibrillation (AF) is the most common cause of cardioembolic stroke and is associated with
poor prognosis in survivors after ischemic stroke. AF was reported to increase the annual risk of
cardiovascular events by 5-fold [1,2]. In efforts to prevent cardiovascular events due to AF, researchers
have focused on the identification of patients at high risk of developing cardiovascular events [3].
Several studies have suggested that atherosclerosis is associated with both the development and
the outcome of AF [4]. For example, among the components of the CHAD2DS2-VASc score, age,
hypertension, diabetes, history of stroke/transient ischemic attack, and vascular disease are known to
be the important risk factors for atherosclerosis [5,6].
Carotid atherosclerosis ≥ 50% in patients with AF is well known to be an independent risk factor
for future ischemic stroke and vascular events [7–9]. However, the prognostic implication of carotid
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atherosclerosis < 50% is not well known. Carotid ultrasonography can easily detect mild carotid
atherosclerosis through measurements of the carotid intima media thickness (IMT) and carotid plaque
thickness [8–10]. However, little is known about the prognostic impact of the number of carotid
plaques on the outcome of patients with AF. In this regard, we evaluated the association between the
total carotid plaque number (TPN) and long-term prognosis in ischemic stroke patients with AF.
2. Materials and Methods
2.1. Study Population
This is a hospital-based observational study in ischemic stroke patients who were prospectively
registered to a stroke registry from January 2007 to December 2013 in Severance Hospital, Seoul, South
Korea. [11]. The registry enrolled consecutive patients with acute ischemic stroke within 7 days of
onset. During admission, all patients were evaluated with brain magnetic resonance imaging and/or
computed tomography, as well as cerebral angiography (magnetic resonance angiography, computed
tomography angiography, or digital subtraction angiography). Systemic evaluation included 12-lead
electrocardiography (ECG), chest radiography, standard blood tests, lipid profile, and continuous
ECG monitoring during stay in the stroke unit. Specific evaluation for finding the cardioembolic
source, such as transthoracic echocardiography, transesophageal echocardiography, and 24-h Holter
monitoring was done.
The stroke subtypes according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST)
classification [12] and the presence of angiographic abnormalities were prospectively determined using
neuroradiologist reports and the consensus of stroke specialists in weekly stroke conferences, and
prospectively entered into a computerized database.
This study was approved by the institutional review board of Severance Hospital, Yonsei
University Health System, which waived the requirement for informed consent from patients owing to
the retrospective nature of the analysis.
2.2. Clinical Variables
We collected data on demographics and risk factors of stroke including hypertension, diabetes,
hyperlipidemia, coronary artery disease, peripheral artery disease, history of stroke, transient ischemic
accident or thromboembolism, and smoking habit. Hypertension was defined as a systolic blood
pressure of≥ 140 mmHg or a diastolic blood pressure of≥ 90 mmHg, or any history of anti-hypertensive
agent use. Diabetes was defined as fasting glucose level ≥ 7.0 mmol/L, random blood glucose
level ≥ 11.0 mmol/L, glycated hemoglobin ≥ 6.5%, or a history of oral hypoglycemic agent or
insulin use. Hyperlipidemia was defined as serum total cholesterol ≥ 6.21 mmol/L, low-density
lipoprotein cholesterol ≥ 4.14 mmol/L, or any history of use of lipid-lowering agents after a diagnosis
of hyperlipidemia. AF was diagnosed on the basis of the findings of routine ECG, Holter monitoring,
or continuous ECG monitoring on the current admission or before admission. Paroxysmal AF was
also considered the presence of AF. Congestive heart failure was determined from the history of heart
failure diagnosis, treatment with loop diuretics, and ejection fraction ≤35% on echocardiography.
Coronary artery occlusive disease (CAOD) was defined as any history of unstable angina, myocardial
infarction, and CAOD. Peripheral artery occlusive disease was defined as any history of a diagnosis
of peripheral artery disease at any hospital regardless of the presence or absence of intervention
or medication for peripheral artery disease. Patients were considered current smokers if they had
smoked any cigarettes within 1 year before admission. Medication history including anti-coagulant,
anti-platelet, anti-hypertensive, and lipid-lowering agent use was collected. Laboratory data were
also obtained for complete blood count, lipid profile, blood urea nitrogen level, and creatinine level.
The severity of stroke was determined using the National Institute Health Stroke Scale (NIHSS) score
at admission.
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2.3. Carotid Artery Assessment
Carotid artery plaques were assessed using B-mode ultrasound (iU22 ultrasound system; Philips,
Bothell, WA, USA) with a 3-9-MHz multifrequency linear array transducer. All measurements were
done in a semi-dark room by two trained ultrasonographers. Bilateral longitudinal and transverse
images of the common carotid arteries (CCAs) and internal carotid arteries (ICAs) were always obtained
and the presence of plaque was decided after comparison of longitudinal and transverse images.
The IMT in the CCAs was defined as the distance of the interface between the lumen-intima and the
media-adventitia. The far wall of the carotid artery was visualized bilaterally in the CCAs (20–50 mm
proximal to the bifurcation of blood flow), carotid bulb (0–20 mm proximal to the bifurcation of blood
flow), and internal and external carotid arteries (0–20 mm distal to the bifurcation of blood flow). At 20,
25, and 30 mm proximal to the bifurcation of blood flow, IMT was bilaterally measured at the far wall
of the CCAs during end-diastole, and calculated as the mean value for each patient. According to the
Mannheim criteria [13], carotid plaque was defined as a focal structure encroaching into the arterial
lumen by at least 0.5 mm, > 50% of surrounding IMT values, or thickness ≥ 1.5 mm above the distance
of the interface between the lumen-intima and the media-adventitia.
The thickness of each plaque in the carotid arteries in the whole scanned area was also bilaterally
measured. The TPN was determined by simply counting (bilaterally) the number of plaques in
proximal ICAs and CCAs. The best cutoff values for TPN were determined using the Contal and
O’Quigley method, which calculates the maximum hazard ratio (HR) based on log-rank statistics [14].
2.4. Follow-Up and Outcomes
After discharge, each patient was followed up with regularly at 3 months, 1 year, and yearly
thereafter. At each follow-up visit, medical information including occurrence of any cardiovascular
events, newly detected vascular risk factors, lifestyle modification after stroke, and re-admission
to another hospital was obtained via face-to-face interviews with neurologists or through clinical
research associates in the outpatient clinic. When the patients missed a scheduled visit, we obtained
the information from the patients or their proxy through a telephone interview with a structured
questionnaire [15]. In addition, we also obtained mortality data based on death certificates from the
Korean National Statistical Office (http://www.kostat.go.kr).
The primary end point was major adverse cardiovascular events (MACE; cardiovascular
mortality, non-cardiovascular mortality, and occurrence of non-fatal stroke or myocardial infarction).
Cardiovascular mortality was defined as any mortality due to stroke, myocardial infarction, other
cardiac disease, or unobserved sudden death. The secondary outcome was all-cause mortality. The
censoring date was December 31, 2013.
2.5. Statistical Analysis
The data were presented as mean ± standard deviation or medians (interquartile range [IQR]), as
appropriate. Differences between the two groups were compared with the chi-square test, Fisher’s
exact test, Student’s t-test, and the Mann–Whitney U-test, as appropriate. Survival analysis was
conducted, and survival curves were plotted using Kaplan–Meier analysis. The difference of survival
time between groups was analyzed using a log-rank test. To determine the independent predictor of
MACE and all-cause mortality, Cox proportional hazard regression analysis was used, and HR and
95% confidence interval (CI) values were summarized. Cox proportional hazard regression analysis
was conducted with adjustments for age, sex, initial NIHSS score, and variables with p < 0.1 in the
univariate analysis.
To evaluate the added value of carotid plaque burden for the prognosis of ischemic stroke caused
by AF, we constructed the model incorporating variables in the CHA2DS2-VASc score and other
variables associated with carotid plaque burden such as IMT, maximal carotid plaque thickness, and
TPN. We compared the following five models: (1) CHA2DS2-VASc score variables alone; (2) addition
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of IMT; (3) addition of maximal carotid plaque thickness; (4) addition of TPN; and (5) addition of
IMT, maximal carotid plaque thickness, and TPN. For internal validation of the newly developed
model, time-dependent receiver-operating characteristic curves and areas under the curve (AUCs)
were determined based on Heagerty’s incident / dynamic AUCs during the median follow-up time [16].
A boot strapping method with 1000 re-samplings for calculating the 95% CI and the difference between
the c-indices of each model was applied [17]. All tests were two-sided, and p < 0.05 was considered
statistically significant. Statistical analysis was performed using R software, version 3.1.3 (R Foundation
of Statistical Computing, Vienna, Austria).
3. Results
3.1. Patients’ Characteristics
A total of 3727 consecutive ischemic stroke/transient ischemic attack patients were enrolled during
the study period. After the exclusion of 2896 patients without AF, a total of 831 patients with AF
remained. Among them, 150 patients without carotid ultrasonography and 76 patients with valvular
heart disease were excluded. Patients who had > 50% stenosis in the intracranial or extracranial
arteries (n = 143), complex aortic atheroma (≥ 4 mm or mobile atheroma) (n = 6), lacunar infarction
(n = 50), and other rare etiologies (n = 14) according to the TOAST classification were also excluded.
Finally, a total of 392 patients were analyzed (Figure 1).
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Figure 1. Flow sheet for study patients’ selection. 
The baseline characteristics of the enrolled patients are summarized in Table 1. The mean age of the 
total enrolled patients was 69.2 ± 10.3 years, and 225 (57.5%) patients were men. The median NIHSS score 
at admission was 5.5 (IQR 2–13). Before admission, 88 (22.4%) patients were taking oral anticoagulants. 
Carotid plaques were found in 343 (87.5%) patients. The median TPN was 3 (IQR 2–6). The median IMT 
and plaque thickness was 0.8 (IQR 0.7–0.9) and 2.1 (IQR 1.7–2.9), respectively. The inter-rater reliability 
based on the intraclass correlation coefficient (ICC) between ultrasonographers for carotid duplex 
sonography parameters was excellent, as follows: TPN (ICC: 0.983, p < 0.001), IMT (ICC: 0.966, p < 0.001), 
and maximal plaque thickness (ICC: 0.892, p = 0.001). In case of disagreement between ultrasonographers 
regarding parameters of the carotid duplex sonography, any disagreement was resolved by consensus. 
Following the Contal and O’Quigley method, the patients were categorized into two groups according to 
the best cutoff values for TPN (TPN ≤ 4 vs. TPN ≥ 5). The TPN ≤ 4 group consisted of 239 (71.0%) patients, 
and the TPN ≥ 5 group comprised 153 (39.0%) patients. Patients in the TPN ≥ 5 group were older and more 
likely to have hypertension, CAOD, statin use, or anti-hypertensive drug use. In addition, the TPN ≥ 5 
group had higher IMT (0.9 ± 0.2 vs. 0.8 ± 0.2, p < 0.001) and larger maximal plaque thickness (3.0 ± 0.9 vs. 
1.7 ± 1.1, p < 0.001) than the TPN ≤ 4 group.
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The baseline characteristics of the enrolled patients are summarized in Table 1. The mean age
of the total enrolled patients was 69.2 ± 10.3 years, and 225 (57.5%) patients were men. The median
NIHSS score at admission was 5.5 (IQR 2–13). Before admission, 88 (22.4%) patients were taking oral
anticoagulants. Carotid plaques were found in 343 (87.5%) patients. The median TPN was 3 (IQR 2–6).
The median IMT and plaque thickness was 0.8 (IQR 0.7–0.9) and 2.1 (IQR 1.7–2.9), respectively. The
inter-rater reliability based on the intraclass correlation coefficient (ICC) between ultrasonographers
for carotid duplex sonography parameters was excellent, as follows: TPN (ICC: 0.983, p < 0.001), IMT
(ICC: 0.966, p < 0.001), and maximal plaque thickness (ICC: 0.892, p = 0.001). In case of disagreement
between ultrasonographers regarding parameters of the carotid duplex sonography, any disagreement
was resolved by consensus. Following the Contal and O’Quigley method, the patients were categorized
into two groups according to the best cutoff values for TPN (TPN ≤ 4 vs. TPN ≥ 5). The TPN ≤ 4 group
consisted of 239 (71.0%) patients, and the TPN ≥ 5 group comprised 153 (39.0%) patients. Patients in the
TPN≥ 5 group were older and more likely to have hypertension, CAOD, statin use, or anti-hypertensive
drug use. In addition, the TPN ≥ 5 group had higher IMT (0.9 ± 0.2 vs. 0.8 ± 0.2, p < 0.001) and larger
maximal plaque thickness (3.0 ± 0.9 vs. 1.7 ± 1.1, p < 0.001) than the TPN ≤ 4 group.
Table 1. Clinical characteristics of study patients according to the total carotid plaque number (TPN).
TPN ≤ 4
(N = 239)
TPN ≥ 5
(N = 153) P Value
Demographics
Age, years 66.4 ± 10.5 73.5 ± 8.4 < 0.001
Sex, men 134 (56.1) 91 (59.5) 0.575
Initial NIHSS score 5 (2–13) 6 (2–13) 0.639
Risk factors
Hypertension 155 (64.9) 126 (82.4) < 0.001
Diabetes mellitus 53 (22.2) 46 (30.1) 0.102
Smoking 38 (15.9) 23 (15.0) 0.930
Hyperlipidemia 38 (15.9) 37 (24.2) 0.057
PAOD 5 (2.1) 7 (4.6) 0.275
CAOD 47 (19.7) 50 (32.7) 0.005
CHF 33 (13.8) 21 (13.7) 1.000
Laboratory findings
Hemoglobin, g/dL 14.1 ± 2.1 13.5 ± 1.5 0.001
White blood cell, × 109/L 8202.7 ± 2827.0 7830.1 ± 2939.5 0.211
Platelet, × 109/L 225.6 ± 69.9 224.6 ± 70.0 0.885
Blood urea nitrogen, mmol/L 17.4 ± 6.3 18.8 ± 9.6 0.190
Creatinine, µmol/L 1.0 ± 0.8 1.3 ± 1.6 0.128
Total cholesterol, mmol/L 170.8 ± 35.8 167.2 ± 39.4 0.361
Triglyceride, mmol/L 96.2 ± 50.2 89.5 ± 45.3 0.184
HDL-cholesterol, mmol/L 45.0 ± 11.5 44.8 ± 11.9 0.865
LDL-cholesterol, mmol/L 106.5 ± 32.3 103.6 ± 35.7 0.399
Premorbid medication
Antiplatelet agent 98 (41.0) 76 (49.7) 0.114
Anticoagulants 60 (25.1) 28 (18.3) 0.147
Statin 36 (15.1) 44 (28.8) 0.002
Antihypertensive agent 93 (38.9) 81 (52.9) 0.009
Carotid duplex measurement
IMT, mm 0.8 ± 0.2 0.9 ± 0.2 < 0.001
Maximal plaque thickness, mm 1.7 ± 1.1 3.0 ± 0.9 < 0.001
Total plaque number, n 2 (1–3) 7 (5–10.5) < 0.001
Data are shown as n (%), mean ± SD, or median (IQR). SD, standard deviation; IQR, interquartile range; NIHSS,
National Institute of Health Stroke Scale; PAOD, peripheral artery occlusive disease; CAOD, coronary artery
occlusive disease; CHF, congestive heart failure;; HDL, high density lipoprotein; LDL, low density lipoprotein; IMT,
intimal medial thickness.
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3.2. Outcome
The mean follow-up period was 2.42 ± 1.83 years. During the follow-up, a total of 113 (28.8%)
MACE occurred in 60 (25.1%) patients of the TPN ≤ 4 group and in 53 (34.6%) patients of the TPN ≥ 5
group. In Kaplan–Meier analysis, the TPN ≥ 5 group showed a higher MACE rate than the TPN ≤ 4
group (log-rank test, p< 0.001) (Figure 2A). Multivariate Cox proportional regression analysis showed
that the TPN ≥ 5 group had a significantly higher MACE rate than the TPN ≤ 4 group after adjusting
for age, sex, and variables with p < 0.1 in univariate analysis (adjusted hazard ratio [HR], 1.50; 95% CI,
1.01–2.21; p < 0.05) (Table 2).
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Analysis 
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HR (95% 
CI) 
P 
value 
HR (95% 
CI) 
P 
value 
HR (95% 
CI) 
P 
value 
HR (95% 
CI) 
P value 
Demographics 
Age 
1.05 (1.03–
1.07) 
0.000 
1.04 
(1.01–
1.06) 
0.002 
1.07 (1.05–
1.10) 
0.000 
1.05 
(1.02–
1.08) 
0.003 
Sex 
0.66 (0.45–
0.95) 
0.027 
1.03 
(0.67–
1.59) 
0.887 
0.66 (0.43–
1.00) 
0.051 
0.95 
(0.49–
1.84) 
0.874 
Initial NIHSS score 
1.06 (1.03–
1.08) 
0.000 
1.05 
(1.02–
1.08) 
0.001 
1.07 (1.04–
1.00) 
0.446 
1.07 
(1.03–
1.11) 
0.000 
Risk factors 
Hypertension 
1.32 (0.86–
2.04) 
0.208   
1.21 (0.74–
1.96) 
0.446   
Diabetes mellitus 
1.02 (0.66–
1.56) 
0.933   
1.10 (0.68–
1.78) 
0.106   
Smoking 
1.18 (0.72–
1.93) 
0.512   
1.16 (0.66–
2.02) 
0.603   
PAOD 
1.70 (0.69–
4.18) 
0.247   
2.68 (1.08–
6.65) 
0.033 
1.25 
(0.36–
4.41) 
0.727 
CAOD 
1.51 (1.01–
2.26) 
0.046 
1.14 
(0.75–
1.75) 
0.532 
1.74 (1.11–
2.73) 
0.016 
1.18 
(0.64–
2.16) 
0.588 
i r 2. l i r l i f r ( ) j r r c r i l r t ( ); ( ) all-ca se
rt lit cc r i t t e t tal caroti plaque nu ber (TP ).
In terms of all-cause mortality, 88 (22.4%) patients had died during the follow up period.
In Kaplan–Meier curve analysis, the TPN ≥ 5 group showed a higher mortality rate than the
TPN ≤ 4 group (log-rank test, p < 0.001) (Figure 2B). In multivariate Cox proportional regression
analysis after adjusting for age, sex, and variables with p < 0.10 in univariate analysis, patients in the
TPN ≥ 5 group showed an increased risk of all-cause mortality (adjusted HR, 2.69; 95% CI, 1.40–5.17;
p < 0.05) compared with patients in the TPN ≤ 4 group (Table 2).
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Table 2. Unadjusted and adjusted hazard ratio for MACE and all-cause mortality according to the total
carotid number of plaque.
MACE All-Cause Mortality
Univariate Analysis MultivariateAnalysis Univariate Analysis
Multivariate
Analysis
HR (95%
CI) P Value
HR (95%
CI) P Value
HR (95%
CI) P Value
HR (95%
CI) P Value
Demographics
Age 1.05(1.03–1.07) 0.000
1.04
(1.01–1.06) 0.002
1.07
(1.05–1.10) 0.000
1.05
(1.02–1.08) 0.003
Sex 0.66(0.45–0.95) 0.027
1.03
(0.67–1.59) 0.887
0.66
(0.43–1.00) 0.051
0.95
(0.49–1.84) 0.874
Initial NIHSS
score
1.06
(1.03–1.08) 0.000
1.05
(1.02–1.08) 0.001
1.07
(1.04–1.00) 0.446
1.07
(1.03–1.11) 0.000
Risk factors
Hypertension 1.32(0.86–2.04) 0.208
1.21
(0.74–1.96) 0.446
Diabetes mellitus 1.02(0.66–1.56) 0.933
1.10
(0.68–1.78) 0.106
Smoking 1.18(0.72–1.93) 0.512
1.16
(0.66–2.02) 0.603
PAOD 1.70(0.69–4.18) 0.247
2.68
(1.08–6.65) 0.033
1.25
(0.36–4.41) 0.727
CAOD 1.51(1.01–2.26) 0.046
1.14
(0.75–1.75) 0.532
1.74
(1.11–2.73) 0.016
1.18
(0.64–2.16) 0.588
CHF 1.66(1.05–2.61) 0.029 1.22(0.76–1.97) 0.411
2.31
(1.43–3.72) 0.001
1.72
(0.83–3.57) 0.148
Laboratory findings
Hemoglobin 0.88(0.80–0.95) 0.002
0.91
(0.82–1.01) 0.909
0.86
(0.79–0.94) 0.001
0.94
(0.79–1.11) 0.466
White blood cell 1.00(1.00–1.00) 0.831
1.00
(1.00–1.00) 0.836
Platelet 1.00(1.00–1.00) 0.361
1.00
(0.99–1.00) 0.040
1.00
(0.99–1.00) 0.998
BUN 1.02(0.99–1.05) 0.157
1.03
(1.01–1.06) 0.018
1.01
(0.98–1.05) 0.590
Creatinine 1.05(0.88–1.24) 0.600
1.08
(0.91–1.28) 0.371
Total cholesterol 1.00(0.99–1.00) 0.089
0.99
(0.99–1.00) 0.067
Triglyceride 1.00(1.00–1.00) 0.929
1.00
(0.99–1.01) 0.184
1.00
(1.00–1.00) 0.974
HDL–cholesterol 1.00(0.98–1.01) 0.844
1.00
(0.98–1.02) 0.987
LDL–cholesterol 0.99(0.99–1.00) 0.071
1.00
(0.99–1.00) 0.234
0.99
(0.99–1.00) 0.051
Premorbid medication
Antiplatelet agent 1.03(0.71–1.49) 0.867
1.02
(0.67–1.56) 0.916
Anticoagulants 0.78(0.49–1.23) 0.288 0.83(0.50–1.40) 0.494
Statin 1.41(0.92–2.16) 0.117
1.28
(0.78–2.11) 0.330
Antihypertensive
agent
1.45
(0.99–2.13) 0.056
1.75
(1.13–2.70) 0.011
1.73
(0.89–3.38) 0.106
Total plaque
number
TPN ≤ 4
(reference) 1 1 1 1
TPN ≥ 5 1.82(1.25–2.64) 0.002
1.50
(1.01–2.21) 0.044
2.16
(1.41–3.29) < 0.001
2.69
(1.40–5.17) 0.003
MACE, major adverse cardiovascular events; HR, hazard ratio; CI, confidential interval; National Institute of Health
Stroke Scale; PAOD, peripheral artery occlusive disease; CAOD, coronary artery occlusive disease; CHF, congestive
heart failure; BUN, blood urea nitrogen; HDL, high density lipoprotein; LDL, low density lipoprotein; IMT, intimal
medial thickness.
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3.3. Prognostic Utility of Carotid Plaque Burden on Ischemic Stroke Caused by AF
During the median follow-up period, the c-indices of Heagerty’s incident/dynamic AUC of each
model were calculated (Table 3 and Supplementary Figure S1). The baseline model consisted of age,
sex, congestive heart failure, diabetes mellitus, CAOD, and peripheral artery occlusive disease, which
are the same variables of the CHAD2DS2-VASc score. The c-index for the baseline model was 0.651
(95% CI, 0.605–0.705) in MACE and 0.712 (95% CI, 0.658–0.766) in all-cause mortality. In model 5,
including of all parameters of carotid plaque burden including TPN, maximal plaque thickness, and
IMT improved prognostic utility that with the CHAD2DS2-VASc score alone in MACE (c-index, 0.686,
95% CI, 0.638–0.737, p = 0.045) and all-cause mortality (c-index, 0.734, 95% CI (0.686–0.786, p = 0.025).
Table 3. C-indices of Heagerty’s incident/dynamic AUC for predicting MACE and all-cause mortality
MACE All–Cause Mortality
c–Index
(95% CI) Difference P–Value c–Index Difference P–Value
Model 1 ∗ 0.651(0.605–0.705) Reference
0.696
(0.647–0.753) Reference
Model 2 † 0.661(0.613–0.714)
0.010
(−0.005–0.033) 0.267
0.712
(0.658–0.766)
0.016
(−0.005–0.046) 0.218
Model 3 ‡ 0.672(0.626–0.726)
0.020
(0.001–0.049) 0.214
0.716
(0.670–0.769)
0.019
(0.001–0.045) 0.113
Model 4 §
0.657
(0.609–0.710)
0.006
(0–0.022) 0.317
0.701
(0.651–0.756)
0.005
(−0.001–0.021) 0.405
Model 5 ‖ 0.686(0.638–0.737)
0.034
(0.006–0.071) 0.045
0.734
(0.686–0.786)
0.038
(0.006–0.075) 0.025
AUC, area under the curve; MACE, major adverse cardiovascular events; CI, confidence interval. ∗ Model 1:
CHA2DS2-VASc variables (age, sex, hypertension, diabetes mellitus, congestive heart failure, coronary artery
occlusive disease, peripheral artery occlusive disease) †Model 2: Model 1 plus carotid intima medial thickness; ‡
Model 3: Model 1 plus total number of plaque; § Model 4: Model 1 plus maximal thickness of plaque; ‖Model 5:
Model 1 plus carotid intima medial thickness plus maximal plaque thickness plus total number of plaque.
4. Discussion
The present study revealed that carotid plaque burden of < 50% carotid stenosis was a strong
prognostic marker in patients with AF. Among the parameters of carotid plaque burden, TPN is easily
counted during carotid ultrasonography examination. It showed an impact on the outcome of ischemic
stroke patients with AF. Moreover, the carotid plaque burden improved the predictive value of the
CHAD2DS2-VASc score in predicting cardiovascular events and mortality in ischemic stroke patients
with AF.
AF is the most common cause of cardioembolic stroke. Patients with AF had markedly reduced
survival compared with those without AF. In the Framingham Heart Study, the risk factor-adjusted
odds ratio for death was 1.5 and 1.9 in men and women, respectively [18]. Patients with AF frequently
have concomitant cerebral atherosclerosis (20–50% of cases) [19,20]. It is well known that atherosclerosis
is a systemic disorder that plays an important role in the prognosis of patients with AF [4]. It can be
assumed that patients with AF are more likely to have additional atherosclerotic burden and may have
poor prognosis. We previously reported that patients who have both large artery atherosclerosis (>50%
atherosclerotic stenosis in the relevant artery) and cardioembolism showed higher cardiovascular
mortality than patients with a single cause of either large artery atherosclerosis or cardioembolism [21].
Thus, it can be inferred that concomitant carotid atherosclerosis with AF is associated with the
development of cardiovascular events despite the presence of < 50% stenosis.
To date, little is known about the impact of < 50% atherosclerotic stenosis of the carotid artery
on the outcome of ischemic stroke patients with AF. The presence of large artery atherosclerosis can
be screened using luminography including computed tomography angiography, magnetic resonance
angiography, or digital subtraction angiography. However, arterial wall changes including small
J. Clin. Med. 2019, 8, 1897 9 of 11
plaques or increased IMT in the carotid artery cannot be detected using luminography. Carotid
ultrasonography is a noninvasive imaging examination that can easily and accurately evaluate carotid
plaques and IMT in the arterial lumen.
We found that the TPN ≥ 5 group had a 1.5-fold higher MACE rate than the TPN ≤ 4 group after
adjustments. Moreover, considering all parameters of carotid plaque burden, including TPN, maximal
plaque thickness, and IMT, contributed to the improvement of the risk stratification of ischemic
stroke patients with AF over that with the CHAD2DS2-VASc risk score alone. The components of the
CHAD2DS2-VASc score are clinical variables including old age, hypertension, diabetes, and vascular
disease. These variables are also well-known risk factors for atherosclerosis [6]. Therefore, adding the
carotid plaque burden to the model improves the risk prediction.
In line with our findings, cohort studies including non-stroke patients also reported similar
results. In ARAPACIS (Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment:
Collaborative Italian Study), a prospective nationwide observational cohort study in patients with
non-valvular AF, the investigators reported that carotid plaque detection improves the predictive
value of the CHAD2DS2-VASc score in patients with AF [22]. The ARIC (Atherosclerosis Risk in
Communities) study investigators also reported that carotid IMT and the presence of carotid plaque
are associated with an increased risk of ischemic stroke in patients with AF. The addition of carotid
IMT and carotid plaque to the model provided an incremental predictive value for the risk of stroke
over the CHAD2DS2-VASc score alone in adults with AF who had no prior ischemic stroke. Although
we reached similar findings, a difference of the present study from the two cohort studies is that we
enrolled only ischemic stroke patients with AF. Another difference is that we adopted TPN because
this variable can be easily and acutely measured on routine carotid ultrasonography [10].
Currently, the method for the secondary prevention of ischemic stroke caused by AF is
anticoagulation with a vitamin K antagonist or a direct oral anticoagulant (DOAC) [23]. However,
vitamin K antagonists can prevent only 67% of future ischemic stroke events and DOAC did not show
superiority over vitamin K antagonists [24,25]. Identification of high-risk patients for future events
despite anticoagulation treatment is important. Carotid atherosclerosis and atherosclerotic burden
can be easily detected using carotid duplex ultrasonography. Although TPN is less accurate and
operator-dependent method than quantification measurement of carotid plaque such as total plaque
area [26,27], TPN can be easily counted and may be helpful in identifying high risk patients in daily
clinical practice. Our study has several limitations. First, unstable plaque morphology and hypoechoic
plaque are associated with an increased risk of ischemic stroke; however, we did not analyze the
characteristics of individual plaques. Nevertheless, unstable carotid plaque is known to be prevalent
in advanced carotid atherosclerosis, and our study did not include patients with >50% stenosis in an
intracranial or extracranial artery. Thus, the influence of the morphologic feature of carotid plaques
may be little. Second, carotid duplex ultrasonography was conducted by two ultrasonographers;
however, the measurement agreement between them was high. Third, potential selection bias may
exist. To minimize selection bias, we recruited consecutive ischemic stroke patients with AF.
5. Conclusions
In conclusion, TPN is an important risk predictor in ischemic stroke patients with AF. In addition,
considering all parameters of carotid plaque burden including TPN, maximal plaque thickness, and
IMT may contribute to improving the risk prediction in ischemic stroke patients with AF, compared
with the prediction with the clinical variables of CHAD2DS2-VASc score alone. These findings suggest
that carotid ultrasonography may be useful in reclassifying these patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/11/1897/s1,
Figure S1. The c-indices of Heagerty’s incident/dynamic AUC of each model (A) major adverse cardiovascular
event (MACE); (B) all-cause mortality.
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